Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M …
网页3 天之前 · The deal amount represents 5.8% of Yuhan’s latest yearly sales of 1.85 trillion Korean won ($1.4 billion), according to a filing. Yuhan co-promotes several Gilead HIV drugs, including the ...
Yuhan Signs KRW107.7 Billion Deal with Gilead Sciences for HIV ...
网页16 小时之前 · Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as …
Yuhan inks $80.9M deal with Gilead Sciences for HIV drug …
网页3 天之前 · Yuhan has secured an $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drugmaker announced in an electronic disclosure on Friday. The contract runs through Sept. 30, 2025, according to the regulatory filing.
The top 1% of stock investment returns were net buyers of Yuhan ...
网页14 小时之前 · Yuhan Corporation's stock price was 144,900 won as of 9:30 a.m., down 0.34% from the previous trading day. On the 20th of last month, Yuhan Corporation received approval from the U.S. FDA for its non-small cell lung cancer treatment "Lekraza". This is the first time that a domestic anticancer drug has been approved by the FDA.
Yuhan inks $81 mn contract with U.S. Gilead to supply HIV …
网页3 天之前 · South Korean pharmaceutical company Yuhan Corp. announced on Friday that it has signed a contract with U.S. biopharmaceutical company Gilead Sciences Inc. to supply raw materials for human immunodeficiency virus (HIV) treatments. The contract is worth 107.6 billion won ($80.8 million), which is 5.79 percent of Yuhan’s sales in 2023.
Yuhan, Janssen halt next-gen cancer drug collaboration - The …
网页3 天之前 · Yuhan's corporate logo (Yuhan) South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the development of a next-generation targeted ...
Yuhan set to receive $60 m from Janssen for ... - 조선일보
网页2024年9月12日 · Yuhan Corporation announced on Sep 11., via a regulatory filing, that it will receive a $60 million (about 80.4 billion won) milestone payment from Janssen Biotech, a subsidiary of Johnson & Johnson, following the successful commercialization of its out-licensed anticancer drug, Lazertinib (marketed in Korea as Leclaza).
Yuhan nabs Ubix cancer drug for ₩150B; YH-35995 trial cleared
网页2024年7月1日 · Yuhan Corp., of Seoul, South Korea, has inked a ₩150 billion (US$108.6 million) deal with Korean biotech Ubix Therapeutics Inc. to gain exclusive global rights to UBX-103, Ubix’s oral small-molecule androgen receptor (AR) degrader for prostate cancer.
Yuhan Corporation (000100.KS) Stock Price, News, Quote
网页Find the latest Yuhan Corporation (000100.KS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Yuhan to pay ₩208B for Cyrus-Kanaph’s SOS1 inhibitor for cancer
网页2024年3月8日 · Yuhan Corp., of Seoul, South Korea, added a new potential cancer drug to its oncology pipeline, licensing a son of sevenless homolog 1 (SOS1) inhibitor co-developed by Cyrus Therapeutics Inc. and Kanaph Therapeutics …
- 某些结果已被删除